Prostate cancer (PCa) is the second most common solid tumor in men and the fifth cause of cancer mortality,[1] with an estimate of 288,300 new cases and 34,700 deaths in the United States in 2023.[2] Currently, the cornerstones of PCa management include serum prostate-specific antigen (PSA) quantification, digital rectal examination, and systemic transrectal ultrasound-guided biopsies.[3] Molecular biomarkers supplement existing clinicopathologic tools for PCa diagnosis and prognosis by providing additional and valuable information about the biological behavior of PCa. This evidence concerns the gene KLK3 and posterior cortical atrophy.